CoChat

Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus [RETIRED]: A Report of the AAN Guidelines Subcommittee

Open access
Day, Gregory S., Scarmeas, Nikolaos, Dubinsky, Richard, Coerver, Katherine, Mostacero, Anitra, West, Brooks, Wessels, Scott R., Armstrong, Melissa J. · 2022 · Neurology
Cited by 39

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To identify the class of evidence for aducanumab use for the treatment of Alzheimer disease and present clinical considerations regarding use. METHODS: The author panel systematically reviewed available clinical trial data detailing aducanumab use in individuals with early symptomatic Alzheimer disease. Level of evidence statements were assigned in accordance with the American Academy of Neurology's 2017 therapeutic classification of evidence scheme. Safety information, regulatory decisions, and clinical context were also reviewed. RESULTS: Data were identified from 4 clinical trials, 1 rated Class I and 3 rated Class II. The Class I study showed that single doses of aducanumab up to 30 mg/kg were safe and well tolerated. All 3 Class II studies provided evidence that aducanumab (3-10 mg/kg) decreased amyloid deposition on brain PET at 1 year vs placebo. Efficacy data in the Class II studies varied by dose and outcome, but aducanumab either had no effect on mean change on the Clinical Dementia Rating Sum of Boxes scores or resulted in less worsening (vs placebo) that was of uncertain clinical importance. Adverse amyloid-related imaging abnormalities occurred in approximately 40% of individuals treated with aducanumab vs 10% receiving placebo. CLINICAL CONTEXT: Administration of aducanumab will require expanded clinical infrastructure. Evidence-based guidance is needed to address key questions (e.g., safety in populations not enrolled in phase 3 studies, expected benefits on daily function, treatment duration) and critical issues relating to access to aducanumab (e.g., coverage, costs, burden of monthly infusions) that will inform shared decision making between patients and providers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000200176This paper is marked retracted.

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 39

Metadata

Authors
Day, G. S., Scarmeas, N., Dubinsky, R., Coerver, K., Mostacero, A., West, B., Wessels, S. R., & Armstrong, M. J.
Venue
Neurology
Published
2022-04-12
Volume
98
Issue
15
Pages
619-631
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W4213433015
Cited by
39
References
9
FWCI
5.01
Type
journal article
Language
en
Status
Retracted
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus [RETIRED]: A Report of the AAN Guidelines Subcommittee. https://app.cochat.ai/papers/10.1212/wnl.0000000000200176
The paper
Day, G. S., Scarmeas, N., Dubinsky, R., Coerver, K., Mostacero, A., West, B., Wessels, S. R., & Armstrong, M. J. (2022). Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus [RETIRED]: A Report of the AAN Guidelines Subcommittee. Neurology. https://doi.org/10.1212/wnl.0000000000200176

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.